Blackstone Commits $250 Million to Anagram Therapeutics, Targeting Cystic Fibrosis Complication
Blackstone Life Sciences invests $250 million in Anagram Therapeutics to develop a new drug for cystic fibrosis patients with EPI. This could mean fewer pills daily.
#CysticFibrosis, #Blackstone, #AnagramTherapeutics, #EPI, #DrugDevelopment
https://newsletter.tf/blackstone-gives-250m-to-help-cf-patients/









